Skip to main content
. 2020 Jan 31;11:93. doi: 10.3389/fimmu.2020.00093

Figure 1.

Figure 1

hBD2 reduced the pro-inflammatory effect of LPS and Pam3CSK4 in human primary PBMC's. PBMC's were challenged with LPS (20 pg/ml) or Pam3CSK4 (0.3 μg/ml), respectively, and treated with various concentrations of hBD2 (100, 40, 10, or 1 μg/ml). Release of (A) IL-1β and (B) TNF-α. Results are presented as mean ± SEM, (A) and (B) n = 150–194. Statistical analysis was performed by one-way ANOVA with Bonferroni post-test.